Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Nonsegmental Vitiligo (Tranquillo)
NCT05583526Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Countries
- 15
01
Overview
A Phase 3 trial of ritlecitinib tosilate in nonsegmental vitiligo (NSV), sponsored by Pfizer. Started Dec 2022; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT05583526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583526.